IQWIG Finds No Added Benefit With Novo’s Xultophy Or Lundbeck’s Brintellix
This article was originally published in The Pink Sheet Daily
Executive Summary
The preliminary evaluation now goes to Germany’s Federal Joint Committee to make a final decision on the products’ usefulness in the country’s health care system, and their future pricing.
You may also be interested in...
Takeda Aims To Turn Brintellix Into CNS Cornerstone, Arm-In-Arm With Lundbeck
Multimodal antidepressant Brintellix (vortioxetine) represents Takeda’s first shot at a major depression launch and the future for Lundbeck as blockbuster Lexapro fades into the distance. Time will tell if the partners have what it takes to compete in a highly genericized market; evidence of cognitive benefits could help.
Merck KGaA's Diversified Business Model Proves Its Worth During Pandemic
Germany’s Merck KGaA rapidly expanded its life sciences services business to support the manufacture of COVID-19 vaccines during 2020, and also expects cancer and multiple sclerosis products to fuel its sales growth in coming years.
UCB Aims To Tailor Myasthenia Gravis Therapy Options To Patients
Belgium’s UCB Pharma is expecting progress with new candidates for myasthenia gravis, psoriasis and osteoporosis this year.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: